JO Lindsay

1.3k total citations
24 papers, 948 citations indexed

About

JO Lindsay is a scholar working on Genetics, Surgery and Molecular Biology. According to data from OpenAlex, JO Lindsay has authored 24 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 8 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in JO Lindsay's work include Inflammatory Bowel Disease (11 papers), Microscopic Colitis (5 papers) and Gut microbiota and health (5 papers). JO Lindsay is often cited by papers focused on Inflammatory Bowel Disease (11 papers), Microscopic Colitis (5 papers) and Gut microbiota and health (5 papers). JO Lindsay collaborates with scholars based in United Kingdom, United States and Australia. JO Lindsay's co-authors include Ajay Patel, Laurent Peyrin‐Biroulet, Adeline Germain, Neil E. McCarthy, Kevin Whelan, Charlotte Hedin, Alessandro Armuzzi, S C Knight, Amy Lewis and Siew C. Ng and has published in prestigious journals such as Gut, Alimentary Pharmacology & Therapeutics and Proceedings of The Nutrition Society.

In The Last Decade

JO Lindsay

22 papers receiving 903 citations

Peers

JO Lindsay

GENET

SURGE

GASTR

Chiara Sorini Sweden

Kazuya Takahama Japan

Eishin Ogawa Japan

Allen T. Yu United States

Veerle Bulteel Belgium

Lu Song China

O. Schneider Germany

Florian Tran Germany

Ilaria Cosorich Italy

Kaline Arnauts Belgium

Chiara Sorini Sweden

JO Lindsay

592 ×1.3

276 ×0.7

GENET

44 ×0.2

121 ×0.6

SURGE

124 ×0.7

GASTR

Citations per year, relative to JO Lindsay JO Lindsay (= 1×) peers Chiara Sorini

Countries citing papers authored by JO Lindsay

Since Specialization

Citations

This map shows the geographic impact of JO Lindsay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JO Lindsay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JO Lindsay more than expected).

Fields of papers citing papers by JO Lindsay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JO Lindsay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JO Lindsay. The network helps show where JO Lindsay may publish in the future.

Co-authorship network of co-authors of JO Lindsay

This figure shows the co-authorship network connecting the top 25 collaborators of JO Lindsay. A scholar is included among the top collaborators of JO Lindsay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JO Lindsay. JO Lindsay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Feagan, B G, JO Lindsay, Ana P. Lacerda, et al.. (2023). OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies. Journal of Crohn s and Colitis. 17(Supplement_1). i22–i25. 2 indexed citations

Lindsay, JO, et al.. (2022). CO95 A Matching-Adjusted Indirect Comparison of Filgotinib Versus Tofacitinib for Moderately to Severely Active Ulcerative Colitis. Value in Health. 25(7). S321–S321. 1 indexed citations

Panés, Julián, Peter Higgins, JO Lindsay, et al.. (2022). P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance. Journal of Crohn s and Colitis. 16(Supplement_1). i373–i374. 3 indexed citations

Rossi, Megan, Özge Eyice, Miranda Lomer, et al.. (2020). Prebiotic β-galacto-oligosaccharide impact on clinical, inflammatory and microbiota outcomes in active ulcerative colitis: an open-label study. Proceedings of The Nutrition Society. 79(OCE1). 1 indexed citations

Cox, Selina, Alexis C Prince, Peter M. Irving, et al.. (2017). Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial. Proceedings of The Nutrition Society. 76(OCE4). 3 indexed citations

Giles, Edward, Theodore J. Sanders, Neil E. McCarthy, et al.. (2016). Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease. Mucosal Immunology. 10(1). 184–193. 25 indexed citations

Younge, Lisa, Alex Allepuz, Andrew J. Thompson, et al.. (2015). PTH-083 Selective monitoring of antitnf drug levels and antibodies will reduce short-term prescribing costs and provide early personalised tailoring of antitnf therapy in routine ibd practice. A443.1–A443. 1 indexed citations

Staudacher, Heidi M., Miranda Lomer, JO Lindsay, Peter M. Irving, & Kevin Whelan. (2015). OC-103 The impact of low fodmap dietary advice and probiotics on symptoms in irritable bowel syndrome: a randomised, placebo-controlled, 2 × 2 factorial trial. A51.1–A51. 5 indexed citations

Kennedy, Nicholas A., JO Lindsay, JN Gordon, et al.. (2015). OC-009 Withdrawal of anti-tnf following sustained remission for inflammatory bowel disease: a systematic review and meta-analysis. A5.1–A5. 1 indexed citations

10.

Campbell, S., et al.. (2014). PWE-071 Efficacy Of Infliximab As Second-line Biologic In Crohn’s Disease. Gut. 63(Suppl 1). A154.2–A155. 1 indexed citations

11.

Biancheri, Paolo, et al.. (2014). PWE-087 Interleukin-17a Homodimer Reduces Pro-inflammatory Cytokine Production By Inflammatory Bowel Disease Mucosa Cultured Ex Vivo. Gut. 63(Suppl 1). A162.1–A162.

12.

Felice, Carla, Amy Lewis, Alessandro Armuzzi, JO Lindsay, & Andrew Silver. (2014). Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics. 41(1). 26–38. 95 indexed citations

13.

Hedin, Charlotte, Chris Gast, Geraint B. Rogers, et al.. (2014). OC-051 Siblings Of Crohn’s Disease Patients Exhibit A Biologically Relevant Dysbiosis In The Mucosal Microbial Community: A 16s Rrna Gene Pyrosequencing Study. Gut. 63(Suppl 1). A25.1–A25. 2 indexed citations

14.

Andreyev, Jervoise, Karen Thomas, Barbara Benton, et al.. (2012). OC-083 Optimising radiation bowel injury therapy, the orbit study, a randomised controlled trial. Gut. 61(Suppl 2). A36.1–A36. 1 indexed citations

15.

Benjamin, Jane, Charlotte Hedin, Siew C. Ng, et al.. (2011). Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut. 60(7). 923–929. 252 indexed citations

16.

Hedin, Charlotte, et al.. (2009). Probiotic and prebiotic use by patients with inflammatory bowel disease. Proceedings of The Nutrition Society. 68(OCE1).

17.

Lindsay, JO. (2005). Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut. 55(3). 348–355. 315 indexed citations

18.

Lindsay, JO, Jervoise Andreyev, Panagiotis Vlavianos, & David Westaby. (2004). Self‐expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass. Alimentary Pharmacology & Therapeutics. 19(8). 901–905. 44 indexed citations

19.

Mumford, Andrew, et al.. (1997). Hyperferritinaemia in the absence of iron overload. Gut. 41(3). 408–410. 32 indexed citations

20.

Maywood, Elizabeth S., JO Lindsay, Jonathan Karp, et al.. (1992). The Effect of Signal Frequency on the Gonadal Response of Male Syrian Hamsters to Programmed Melatonin Infusions. Journal of Neuroendocrinology. 4(1). 37–44. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact